Turn the Beat Around-Remix: Atrial Fibrillation Guidelines-2014 Updates
|
|
- Raymond Leonard
- 8 years ago
- Views:
Transcription
1 Turn the Beat Around-Remix: Atrial Fibrillation Guidelines-2014 Updates Brittany Karns, PharmD Alaska Pharmacists Association Annual Conference
2 Disclosures I have no actual or potential conflicts of interest in relation to this presentation. 2
3 Objectives for Learning: 1. Summarize the major updates to the 2014 AHA/ACC/HRS Atrial Fibrillation Guidelines. 2. Calculate a patient s CHA 2 DS 2 -VASc score. 3. Describe current recommendations for aspirin use in AFib. 4. Compare and contrast FDA approved target specific oral anticoagulant agents. 5. Outline appropriate bridging therapy for oral anticoagulation interruptions for AFib patients. 3
4 A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society - American Heart Association - American College of Cardiology - Heart Rhythm Society - Society of Thoracic Surgery 4
5 Intent To assist clinicians in clinical decision making by describing a range of generally acceptable approaches to the diagnosis, management, and prevention of specific diseases or conditions. - Attempt to define practices that meet the needs of most patients - Ultimate judgment must be made by the clinician and patient - Deviations may be appropriate - Engage the patient s active participation 5
6 Methodology Evidence Based Clinicians - Cardiology - Electrophysiology - Cardiothoracic surgery - Heart failure Organization thematic with recommendations - Introduction/Methodology - Background and Pathophysiology - Clinical Evaluations and Recommendations - Prevention of Thromboembolism: Anticoagulation - Rate Control - Rhythm Control - Specific Patient Groups 6
7 Guideline Updates in a Nutshell: - Overall Rehaul - Updated Classification of Treatment Effect - More Pathophysiology/Background - Improved Charts - Revised Definitions - Updated Stroke Risk Calculator: CHA 2 DS 2 -VASc - Reduced Indications for Aspirin Therapy - Addition of Target-Specific Oral Anticoagulants - Dabigatran, Rivaroxaban, Apixaban, (Edoxaban) - Increased Role for Ablation 7
8 Updated Classification of Criteria: Guidance Directed Medical Therapy Classification of Recommendation: Estimate of the size of the treatment effect Separation of Class III recommendations: - Recommendation is of no benefit - Recommendation is of associated with harm Level of Evidence: Estimate of the certainty of the precision of the treatment effect Added Recommendations Phraseology: - Comparator verbs - Suggested phrases for writing recommendations 8
9
10
11 Pathophysiology/Background 11
12 Improved Charts 12
13 Web Tools Available 13
14 Term Simplified Definitions: Paroxysmal AF Definition AF that terminates spontaneously or with intervention within 7 days of onset. Episodes may recur with variable frequency. Persistent AF Continuous AF that is sustained >7 days. Longstanding AF Continuous AF of >12 months duration. Permanent AF Permanent AF is used when there has been a joint decision by the patient and clinician to cease further attempts to restore and/or Non-Valvular AF maintain sinus rhythm. Acceptance of AF represents a therapeutic attitude on the part of the patient and clinician rather than an inherent pathophysiological attribute of the AF. Acceptance of AF may change as symptoms, the efficacy of therapeutic interventions, and patient and clinician preferences evolve. AF in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair. 14
15 Guideline Updates: - Overall Rehaul - Updated Classification of Treatment Effect - More Pathophysiology/Background - Improved Charts - Revised Definitions - Updated Stroke Risk Calculator: CHA 2 DS 2 -VASc - Reduced Indications for Aspirin Therapy - Addition of Target-Specific Oral Anticoagulants - Dabigatran, Rivaroxaban, Apixaban, (Edoxaban) - Increased Role for Ablation 15
16 Old, Familiar Tool: Clinically relevant non-major risk factors: Score: C Congestive Heart Failure/LV Dysfunction 1 H Hypertension 1 A Age 65 years 1 D Diabetes Mellitus 1 S 2 Stroke (TIA/TE) 2 16
17 Gender Correlation with AFib: Women more likely to have stroke! JAMA 2001;285:
18 % Age Correlation with Stroke: AF Prevalence Strokes Attributable to AF Age Range (year) Wolf et al. Stroke 1991;22:
19 Newer Tool: Clinically relevant non-major risk factors: Score: C Congestive Heart Failure/LV Dysfunction 1 H Hypertension 1 A 2 Age 75 years 2 D Diabetes Mellitus 1 S 2 Stroke (TIA/TE) 2 V Vascular Disease (previous MI, PAD, aortic plaque) 1 A Age Years 1 Sc Sex Category (female) 1 - CHA 2 DS 2 -VASc score recommended to assess stroke risk (I-B) 19
20 Practice: What are the CHA 2 DS 2 -VASc scores of the following patients newly diagnosed with atrial fibrillation? - 62 year old male with renal dysfunction, gout, htn, and previous MI who hates exercising and has BMI year old female with CHF, htn, DMII, previous stroke, and PAD who lives alone with her dog Tricky-Woo - 45 year old male with PTSD, hyperlipidemia, and chronic knee pain - 45 year old female with PTSD, hyperlipidemia, and chronic knee pain 20
21 Risk Category CHADS 2 Score Recommended Antithrombotic Therapy No risk factors: 0 No Antithrombotic Therapy One 'clinically relevant non-major' risk factor: 1 Aspirin mg daily One 'major' risk factor or 2 'clinically relevant non-major' risk factors 2 Oral Anticoagulation 21
22 Risk Category CHA 2 DS 2 - VASc Score Recommended Antithrombotic Therapy No risk factors: 0 No Antithrombotic Therapy (preferred) Or Aspirin mg Daily One 'clinically relevant non-major' risk factor: 1 Oral Anticoagulation (preferred) or Aspirin mg Daily One 'major' risk factor or 2 'clinically relevant non-major' risk factors 2 Oral Anticoagulation 22
23 Practice: What therapy is indicated for each of the patient s we discussed (No therapy, ASA, Oral Anticoagulant)? - 62 year old male with CHA 2 DS 2 -VASc score of 2-87 year old female with CHA 2 DS 2 -VASc score of 9-45 year old male with CHA 2 DS 2 -VASc Score of 0-45 year old female with CHA 2 DS 2 -VASc score of 1 23
24 CHA 2 DS 2 -VASc Represents A Practice Shift: Better stratification Greater focus on identification of truly low-risk patients - Need to more INclusive of common stroke RFs 24
25 CHA 2 DS 2 -VASc Represents A Practice Shift: Stroke Risk Stratification Score CHADS2 CHA 2 DS 2 -VASc 0 1.9% 0.0% 1 2.8% 1.3% 2 4.0% 2.2% 3 5.9% 3.2% 4 8.5% 4.0% % 6.7% % 9.8% 7 9.6% 8 6.7% % 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: Europace Aug 24 25
26 Guideline Updates: - Overall Rehaul - Updated Classification of Treatment Effect - More Pathophysiology/Background - Improved Charts - Revised Definitions - Updated Stroke Risk Calculator: CHA 2 DS 2 VASc - Reduced Indications for Aspirin Therapy - Addition of Target-Specific Oral Anticoagulants - Dabigatran, Rivaroxaban, Apixaban, (Edoxaban) - Increased Role for Ablation 26
27 Risk Category CHA 2 DS 2 - VASc Score Recommended Antithrombotic Therapy No risk factors: 0 No Antithrombotic Therapy (preferred) Or Aspirin mg Daily One 'clinically relevant non-major' risk factor: 1 Oral Anticoagulation (preferred) or Aspirin mg Daily One 'major' risk factor or 2 'clinically relevant non-major' risk factors 2 Oral Anticoagulation 27
28 Aspirin vs Warfarin in AF Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:
29 WARFARIN vs PLACEBO ANIPLATELET vs PLACEBO 0 62% 19% WARFARIN vs ANIPLATELET 22% Adapted with permission from Hart et al. 36%
30 Aspirin Therapy: No studies show benefit for aspirin alone in preventing stroke - Warfarin vs ASA ASA inferior to warfarin with higher bleed risk (BAFTA) - Clopidogrel + ASA < Wararin - in pts with mean CHADS 2 of 2 - Clopidogrel + ASA > ASA alone for prevention, but 57% inc in bleeding, minimal differences between the two - Apixaban vs ASA 5mg daily vs asa 81 or 325mg terminated prematurely due to apixaban superiority (AVERROES) 30
31 Aspirin Therapy: No studies show benefit for aspirin alone in preventing stroke - BAFTA Warfarin superior in stroke preventin and equal in bleed - AVERROES: Apixaban vs ASA 5mg daily vs asa 81 or 325mg terminated prematurely due to apixaban superiority 31
32 Guideline Updates: - Overall Rehaul - Updated Classification of Treatment Effect - More Pathophysiology/Background - Improved Charts - Revised Definitions - Updated Stroke Risk Calculator: CHA 2 DS 2 -VASc - Reduced Indications for Aspirin Therapy - Addition of Target-Specific Oral Anticoagulants - Dabigatran, Rivaroxaban, Apixaban, (Edoxaban) - Increased Role for Ablation 32
33 Antithrombotic Therapy: Warfarin and the Target Specific Oral Anticoagulants are all acceptable first line agents for anticoagulation in non-valvular Afib Treatment should be individualized based on shared decision making Target Specific Oral Anticoagulants (TSOACs) - Direct Thrombin Inhibitor Dabigatran - Factor Xa Inhibitors Rivaroxaban, Apixaban (Edoxaban) 33
34 34
35 RE-LY (Dabigatran): Stroke Dabigatran 110mg vs Warfarin Non-inferiority P-value < Superiority P-value 0.34 Dabigatran 150mg vs Warfarin < < Margin = 1.46 Connolly, et al. N Engl J Med 2009;361: HR (95% CI) 35
36 RE-LY (Dabigatran): Efficacy Dabigatran 110 mg Dabigatran 150 mg Stroke/SEE 0.91 ( ) 0.66 ( ) Ischemic Stroke 1.11 ( ) 0.76 ( ) Hemorrhagic Stroke 0.31 ( ) 0.26 ( ) Connolly, et al. N Engl J Med 2009;361: Dabigatran Better Warfarin Better
37 RE-LY (Dabigatran) - Safety Dabigatran 110 mg Dabigatran 150 mg Major Bleed 0.80 ( ) 0.93 ( ) ICH 0.31 ( ) 0.40 ( ) GI Bleed 1.10 ( ) 1.50 ( ) MI 1.29 ( ) 1.27 ( ) Connolly, et al. N Engl J Med 2009;361: Dabigatran Better Warfarin Better 37
38 ROCKET AF (Rivaroxaban) - Stroke Rivaroxaban Warfarin Event Rate Event Rate HR (95% CI) P-value On Treatment N = 14, (0.65, 0.95) ITT N = 14, (0.74, 1.03) Rivaroxaban better Warfarin better Patel, et al. N Engl J Med 2011;365(10);
39 ROCKET AF (Rivaroxaban) - Efficacy Event Rivaroxaban (%/yr) Warfarin (%/yr) Hazard Ratio (95% CI) P-value Ischemic Stroke Hemorrhagic Stroke ( ) ( ) MI ( ) Total Mortality ( ) Vascular Mortality ( ) Patel, et al. N Engl J Med 2011;365(10);
40 ROCKET AF (Rivaroxaban) - Safety Event Major and Clinically Relevant Bleed Rivaroxaban (%/yr) Warfarin (%/yr) Major Bleed Fatal Bleed Hazard Ratio (95% CI) 1.03 ( ) 1.04 ( ) 0.50 ( ) P-value ICH ( ) 0.02 Patel, et al. N Engl J Med 2011;365(10);
41 AVERROES (Apixaban) VS ASPIRIN Stroke or Systemic Embolic Event Major Bleeding Aspirin Apixaban P < Apixaban P < Aspirin HR 0.45 ( ) HR 1.13 ( ) Connolly SJ, et al. N Engl J Med 2011 (epub) 41
42 ARISTOTLE (Apixaban) - Stroke HR 0.79 ( ) (1.60 %/yr) 21% RRR (1.27 %/yr ) P (non-inferiority) < P (superiority) = Granger CB, et al. NEJM 2011; 365:
43 ARISOTLTE (Apixaban) - Efficacy Outcome Stroke or systemic embolism Apixaban (N = 9120) Event Rate (%/yr) Warfarin (N = 9081) Event Rate (%/yr) HR (95% CI) P Value (0.66, 0.95) Stroke (0.65, 0.95) Ischemic or uncertain (0.74, 1.13) 0.42 Hemorrhagic (0.35, 0.75) < Systemic embolism (SE) (0.44, 1.75) 0.70 All-cause death (0.80, 0.998) Stroke, SE, or allcause death Myocardial infarction (0.81, 0.98) (0.66, 1.17) 0.37 Granger CB, et al. NEJM 2011; 365:
44 ARISTOTLE (Apixaban) - Safety Event Apixaban (%/yr) Warfarin (%/yr) Hazard Ratio (95% CI) P-value ISTH Major Bleeding ( ) < ICH ( ) < GUSTO Severe ( ) < Gastrointestinal ( ) 0.37 Granger CB, et al. NEJM 2011; 365:
45 TSOAC Landmark Trials: Pivotal study TSOAC vs. warfarin (INR 2-3) DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN RE-LY Open-label ROCKET-AF Double-blind ARISTOTLE Double-blind ENGAGE-TIMI Double-blind Mean CHADS 2 score Mean Time in Therapeutic Range Efficacy: Reduction in all stroke, systemic embolism Safety: Major bleeding Mortality 64% 55% 62% 68% Superior Non-Inferior Superior Non-Inferior Similar Similar Superior Superior Favorable trend Favorable trend Superior Favorable trend 45
46 TSOAC Indications: - Non-Valvular Atrial Fibrillation - VTE/PE: Apixaban, Rivaroxaban - CHA 2 DS 2 VASc Score 1 46
47 TSOAC Exclusions: - Prosthetic heart valve - Clinically significant valvular disease - Indication other than NVAF Or VTE (Rivaroxaban, Edoxaban) - Following acute stroke or TIA - Active endocarditis - Active pathological bleeding - Known significant liver disease - Previous hypersensitivity reaction - Pregnancy/Breastfeeding - Increased bleeding risk - Anemia (Hgb <10g/dL) or Thrombocyopenia (Plt <100,000/uL) - Hepatic and Renal considerations - Drug-Drug Interactions 47
48 TSOAC Differentiation: Additional indications: - DVT/PE: Rivaroxaban, Edoxaban Administration: - Twice Daily Therapies: Dabigatran, Apixaban - Once Daily Therapies: Rivaroxaban, Edoxaban - Must take with food: Rivaroxaban - Cannot be crushed/opened: Dabigatran Adverse reactions - GI Bleed: Dabigatran, Rivaroxaban - Increased risk of extracranial bleed: Dabigatran - Increased bleeding assoc. age 75yo: Dabigatran, Rivaroxaban - CAD/MI increase: Dabigatran 48
49 TSOAC Differentiation cont: Drug-Drug Interactions - P-Glycoprotein substrate: ALL Inhibitors: (Azoles, verapamil, amiodarone, dronedarone, quinidine, clarithromycin) Inducers: Do NOT use wih Dabigatran, Edoxaban (phenytoin, carbamazepine, rifampin, St Johns wort) - Cyp3A4 substrates: Rivaroxaban, Apixaban Elimination - Mod/severe hepatic impairment (Child-Pugh B&C): Apixaban, Edoxaban - Dialyzable: Dabigatran - Renal limitations: Dabigatran: CrCl <30mL/min Rivaroxaban: CrCl <30mL/min Apixaban: CrCl <25mL/min or serum creatinine (SCr) >2.5 mg/dl Edoxaban : CrCl <50mL/min OR 95mL/min 49
50 TSOAC Monitoring: DO REQUIRE MONITORING - Renal function - Bleeding - Tolerance - Adherence - No routine monitoring of anticoagulation activity DO have some impact on INR 50
51 Items for Consideration: TSOACs vs Warfarin - Cost - Compliance - When level of anticoagulation is desirable - Reversal Options - Access to Health Care Shared Decision Making - Risk factors - Tolerability - Patient Preference - Potential Drug Interactions - Warfarin: Time Therapeutic 51
52 Bridging Switching from WARF DABIGATRAN RIVAROXABAN APIXABAN Edoxaban Start TSOAC when INR <2 Start TSOAC when INR <3 Start TSOAC when INR <2 Star TSOAC when Half-life hours 5-9 hours 12 hours hours Time to Onset 1-2 hours 2-4 hours 3-4 hours 1-2 hours Surgery and Invasive Procedures Anticoagulant Lab testing Discontinue 1-2 days (if CrCl 50 ml/min) or 3-5 days (CrCl <50 ml/min) before invasive procedures or surgery. Consider longer times for higher risk procedures where complete hemostasis is required. None routinely recommended; if urgently needed, aptt, TT (qualitative estimate; presence or absence) Discontinue at least 24 hrs before surgery or procedures with increased bleeding risk. None routinely recommended; if urgently needed, PT, anti-factor Xa (qualitative estimate; presence or absence) Discontinue at least 24 hrs prior to surgery/procedures where risk of bleeding is low and could be easily managed. Discontinue at least 48 hrs prior to surgery/procedures with moderate to high bleeding risk. None routinely recommended; if urgently needed, anti- Factor Xa (qualitative estimate; presence or absence) Discontinue at least 24 hrs prior to surgery/procedures where risk of bleeding is low and could be easily managed. Discontinue at least 48 hrs prior to surgery/procedures with moderate to high bleeding risk. None routinely recommended; if urgently needed, anti-factor Xa (qualitative estimate; presence or absence) 52
53 Antithrombotic Recommendations: 53
54 Antithrombotic Recommendations: 54
55 Guideline Updates: - Overall Rehaul - Updated Classification of Treatment Effect - More Pathophysiology/Background - Improved Charts - Revised Definitions - Updated Stroke Risk Calculator: CHA 2 DS 2 -VASc - Reduced Indications for Aspirin Therapy - Addition of Target-Specific Oral Anticoagulants - Dabigatran, Rivaroxaban, Apixaban, (Edoxaban) - Increased Role for Ablation 55
56 AF Catheter Ablation: Guidelines discuss greater role for Rhythm Control in general Initial Rhythm Control Strategy before pharmacotherapy: - Recurrent symptomatic paroxysmal AF (IIa-B) - Symptomatic persistent AF (IIb-C) Rhythm control patients refractory or intolerant to at least 1 class I or III antiarrhythmic with: - Symptomatic paroxysmal AF (I-A) - Symptomatic persistent AF (IIa-A) - Symptomatic longstanding (>12months) (IIb-B) CLASS III: HARM - Must be able to anticoagulate during and after procedure (III-C) 56
57 AF Catheter Ablation: 57
58 Anticoagulation During Ablation : WARFARIN DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN Good datastandard of care Low quality data; most but not all studies suggest similar thromboembolic/b leeding risk Very limited data; published combined analysis of cardioversion and ablation pts; no difference in outcomes with RIVA vs. WARF in very small number of pts No data No data 58
59 Review/Assessment - Overall Rehaul - Updated Classification of Treatment Effect No Benefit vs Harm - More Pathophysiology/Background - Updated Stroke Risk Calculator: CHA 2 DS 2 VASc What are the new 4 points accounted for in the CHA 2 DS 2 VASc? - Reduced Indications for Aspirin Therapy When is Aspirin preferred? - Addition of Target-Specific Oral Anticoagulants - Which TSOAC is once daily? Which is best - For patients with renal impairment? - Increased Role for Ablation 59
60 Review: - Overall Rehaul - Updated Classification of Treatment Effect No Benefit vs Harm - More Pathophysiology/Background - Updated Stroke Risk Calculator: CHA 2 DS 2 VASc Includes 4 new points (two additional for age, one for vascular disease, one for gender) - Reduced Indications for Aspirin Therapy Almost no situation in which aspirin is preferred - Addition of Target-Specific Oral Anticoagulants - Dabigatran, Rivaroxaban, Apixaban, (Edoxaban) - Increased Role for Ablation 60
61 References: 2014 AHA/ACC/HRS Atrial Fibrillation Guideline 1. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validaion of clinical classification schemes for predicting stroke: results from the National Registry of Arial Fibrillation. JAMA 2001;285(22): Lip GY, Frison L, Halpeirin JL, Lane DA. Identifying patients at high risk for sroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;41(12): Target Specific Oral Anicoagulants (TSOACs) Dabigatran (Pradaxa), Rivaroxaban (Xarelto), and Apixaban (Eliquis) Criteria for Use for Stroke Prevention in Nonvalvular Atrial Fibrillation (AF). VA Pharamacy Benefits Managemen Services Medical Advisory Panel, and VISN Pharmacis Execuives, Coppens et al. The CHA 2 DS 2 -VASc Score Identifies Those Patients With Atrial Fibrillation and a CHADS 2 Score of 1 Who Are Unlikely to Benefit From Oral Anticoagulant Therapy. Eur Heart J. 2013;34(3): Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365: Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. NEJM 2011;365: Giugliano RP, Ruff CF, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. NEJM 2013;369: Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43: Van Gelder IC, Haegeli LM, Brandes A, et al. Rationale and current perspective for early rhythm control 61 therapy in atrial fibrillation. Europace. 2011;13:
62 Thank you! 62
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationStroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationNOAC S For Stroke Prevention in. Atrial Fibrillation. Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health
NOAC S For Stroke Prevention in Atrial Fibrillation Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health New Oral Anti Coagulant Formal Definition: Atrial Fibrillation
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationManaging the Patient with Atrial Fibrillation
Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More informationAF, Stroke Risk and New Anticoagulants
Carmarthen Cardiac Update Course AF, Stroke Risk and New Anticoagulants Dr Hamsaraj Shetty, B.Sc, FRCP (London & Edinburgh) Consultant Physician & Honorary Senior Lecturer University Hospital of Wales,Cardiff
More informationThe New Kids on the Block: Oral Anticoagulants
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
More informationNew Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011
New Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011 Warfarin Decreases stroke risk by 60-70% Superior to ASA and ASA plus clopidogrel
More informationHow To Compare Warfarin To Dabigatran
Page 1 WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation J E A N N A P P I, P H A R M. D., F C C P, B C P S Accreditation: Pharmacists:
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More information} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF
Deniz Yavas, PharmD PGY-2 Ambulatory Care Pharmacy Resident Detroit Veterans Affairs Medical Center } Most common arrhythmia 0.4-1% of Americans (2.2 mil people) 1,2 } Incidence increases with age 6% (65
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More information22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor
Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart
More informationIntroduction. Methods. Study population
New Technologies, Diagnostic Tools and Drugs Schattauer 2012 1 Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a real world atrial fibrillation
More informationOral Anticoagulation in Older Persons The Next Generation
Oral Anticoagulation in Older Persons The Next Generation Luis Viana B.Sc. Phm., Pharm D (candidate), M.Ed., ACPR, CGP Clinical Consultant Pharmacist, Medical Pharmacies Group Limited Adjunct Clinical
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationA focus on atrial fibrillation
A focus on atrial fibrillation Is being female really a risk factor for stroke? Dr Justin Mariani MBBS BMedSci PhD FRACP FCSANZ Consultant Cardiologist and Interventional Heart Failure Specialist Alfred
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationObjectives. Epidemiology. Pathophysiology 4/1/2013
Objectives The New CHEST Guidelines, The Bleeding War Continues Ginger Warren, PharmD., MCSR gwarren@valleyhealthlink.com PGY1 Pharmacy Resident Valley Health System/Bernard J Dunn School of Pharmacy,
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationFrederik Meijer Heart & Vascular Institute
Frederik Meijer Heart & Vascular Institute Evaluation of Atrial Fibrillation in the Outpatient Setting Musa I Dahu, MD, FHRS Electrophysiology Frederik Meijer Heart & Vascular Institute Clinical Assistant
More informationCardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationNIL. Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts. Approach. Approach. 06-Nov-14
Stroke Prevention in Atrial Fibrillation: Commencing Non- Oral Anticoagulants in GP setting Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts Disclosures NIL Classification
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationNORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION
North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial
More informationNew Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Jafna L. Cox, MD, FRCPC, FACC
New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Jafna L. Cox, MD, FRCPC, FACC Heart and Stroke Foundation of Nova Scotia Endowed Chair in Cardiovascular Outcomes Research Director
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationAtrial Fibrillation: New Approaches to an Old Friend PETER JESSEL, MD ASSISTANT PROFESSOR
Atrial Fibrillation: New Approaches to an Old Friend PETER JESSEL, MD ASSISTANT PROFESSOR Disclosures None relevant to this presentation Outline Introduction Natural History and Stroke Risk Stroke/Bleeding
More informationOral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
More informationBridging the Gap: How to Transition from the NOACs to Warfarin
Bridging the Gap: How to Transition from the NOACs to April 24 th 2015 UAN: 0048-0000-15-034-L01-P Amanda Styer, Pharm.D. Marion General Hospital, OhioHealth Objectives: 1. Review labeling regarding transition
More informationElisabetta Toso, MD Dipartment of Medical Sciences University of Turin
Security and efficacy of Rivaroxaban in real life in the prevention of the stroke in non valvular AF patients: presentation of the results of the international study Xantus Elisabetta Toso, MD Dipartment
More informationPerioperative Bridging in Atrial Fibrillation: Is it necessary?
Perioperative Bridging in Atrial Fibrillation: Is it necessary? Jason B. Thompson M.D., Ph.D. August 29, 2015 2015 NCVH Birmingham Hypothesis: When bridging, risk of bleeding < risk systemic embolism (SE).
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationNew Anticoagulants. Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting. 30-Oct-14
Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting A/Prof Michael Nguyen Fremantle Hospital Access Cardiology General Practice Education Day Oct 2014 ORAL TTP889 Rivaroxaban
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationWhat s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
More informationCurrent Controversies in Management of Anticoagulation for Atrial Fibrillation
Current Controversies in Management of Anticoagulation for Atrial Fibrillation Cheri Silverstein Fadlon, MD MSCR Assistant Professor of Internal Medicine, COMP Cardiologist, Western Diabetes Institute
More informationMy approaches to the patients with AF for stroke prevention
10-16-2015 My approaches to the patients with AF for stroke prevention Seongwook Han, MD.PhD. Professor of Medicine, Keimyung University School of Medicine Arrhythmia Service, Cardiology, Dongsan Medical
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationrivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC
rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationNew Treatment Guidelines in Atrial Fibrillation and Updates on NOACs
New Treatment Guidelines in Atrial Fibrillation and Updates on NOACs Dean Schillinger MD Professor of Medicine University of California, San Francisco San Francisco General Hospital & Trauma Center Disclosures
More informationAnticoagulation for NVAF: NAOs or AVKs? Giancarlo Agnelli
Anticoagulation for NVAF: NAOs or AVKs? Giancarlo Agnelli Medicina Interna & Cardiovascolare - Stroke Unit Scuola di Specializzazione in Medicina di Emergenza - Urgenza Università di Perugia My talk today
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More information